Skip to content

Effect of vitamin D supplementation on IL-37 and TNF-a in children with autism spectrum disorders

Effect of vitamin D supplementation on IL-37 and TNF-a in children with autism spectrum disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170827035936N3
Enrollment
50
Registered
2023-09-16
Start date
2023-10-12
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum Disorders. Autistic disorder

Interventions

Intervention 1: Daily vitamin D supplements, 300 units per kilogram of body weight, up to a maximum of 6,000 units for three months are consumed. Intervention 2: Control group: 15 drops of placebo are

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 12 Years

Inclusion criteria

Inclusion criteria: The desire for parental collaboration The age range of 5 to 12 years The diagnosis of autism disorder based on DSM-5 criteria

Exclusion criteria

Exclusion criteria: Reluctance to continue cooperation Children with significant hearing loss and vision loss Other neurological disorders such as cerebral palsy, phenylketonuria, seizure disorders History of head trauma, genetic abnormalities, premature children children with nutritional and malnutrition problems, children with digestive problems children with immune disorders, children with endocrine diseases, cardiovascular, pulmonary, kidney, liver Children two months prior to study Supplements or the following medications, vitamin D, fish liver oil, steroids Children with serum vitamin D levels above 80 ng / ml

Design outcomes

Primary

MeasureTime frame
Serum level of 25 (OH)D3. Timepoint: at the beginning and the end of 12th week. Method of measurement: Elyssa.;Serum level of IL-37. Timepoint: at the beginning and the end of 12th week. Method of measurement: Elyssa.;Serum level of TN F-a. Timepoint: at the beginning and the end of 12th week. Method of measurement: Elyssa.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Javadfar

Kermanshah University of Medical Sciences

zohre.javadfar@yahoo.com+98 83 3427 6301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026